Respiratory Diseases

Influenza, PPSV23 Vaccines May Reduce Risk for COPD Exacerbations, Hospitalizations
July 01, 2022

In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.

Glycopyrrolate/formoterol found Noninferior to Tiotropium/formoterol for Improving COPD Symptoms
June 30, 2022

Authors of this first study to compare the combinations head-to-head suggest that the glycopyrrolate combination is appropriate for long-term COPD management.

Juul Ban Prompts Praise from Physician Organizations
June 24, 2022

The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.

Patients with Moderate or Severe Asthma Benefit from High-intensity Interval Training, Study Finds
June 20, 2022

New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.

FDA Grants EUA for At-home Triple Test: COVID-19, Influenza, RSV
May 23, 2022

The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20, 2022

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
May 19, 2022

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
May 18, 2022

ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
May 17, 2022

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
May 14, 2022

ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.